OptimizeRx (OPRX) News Today $4.94 +0.11 (+2.28%) (As of 01:48 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period OptimizeRx's (OPRX) Buy Rating Reaffirmed at Lake Street CapitalLake Street Capital reissued a "buy" rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday.December 24 at 1:37 PM | marketbeat.comB. Riley Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $13.00B. Riley dropped their target price on OptimizeRx from $17.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday.December 24 at 9:59 AM | marketbeat.comOptimizeRx Corporation Announces CEO Transition and Interim AppointmentDecember 24 at 6:15 AM | americanbankingnews.comOptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEODecember 24 at 3:33 AM | markets.businessinsider.comOptimizeRx affirms FY24 guidance, sees revenue, adjusted EBITDA at higher endDecember 23 at 10:32 PM | markets.businessinsider.comOptimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial OutlookDecember 23 at 10:32 PM | markets.businessinsider.comOptimizeRx CEO William Febbo To Step Down; Names Stephen Silvestro As Interim CEODecember 23 at 5:32 PM | markets.businessinsider.comOptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEODecember 23 at 8:45 AM | globenewswire.comStephens Initiates Coverage on OptimizeRx (NASDAQ:OPRX)December 23 at 4:05 AM | americanbankingnews.comHead-To-Head Contrast: Maplebear (NASDAQ:CART) and OptimizeRx (NASDAQ:OPRX)December 23 at 2:37 AM | americanbankingnews.comStephens & Co. Initiates Coverage of OptimizeRx (OPRX) with Equal-Weight RecommendationDecember 21 at 8:43 AM | msn.comOptimizeRx (NASDAQ:OPRX) Earns Equal Weight Rating from Analysts at StephensStephens started coverage on OptimizeRx in a report on Friday. They set an "equal weight" rating and a $5.50 target price on the stock.December 20, 2024 | marketbeat.comContrasting WNS (NYSE:WNS) & OptimizeRx (NASDAQ:OPRX)December 18, 2024 | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)December 17, 2024 | markets.businessinsider.comInsider Buying: OptimizeRx Co. (NASDAQ:OPRX) CEO Buys 20,000 Shares of StockDecember 17, 2024 | insidertrades.comWilliam J. Febbo Acquires 20,000 Shares of OptimizeRx Co. (NASDAQ:OPRX) StockOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) CEO William J. Febbo purchased 20,000 shares of OptimizeRx stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares of the company's stock, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.December 16, 2024 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to tDecember 9, 2024 | marketbeat.comOptimizeRx to Participate in Upcoming Investor ConferencesNovember 18, 2024 | globenewswire.comOptimizeRx price target lowered to $8 from $13 at StifelNovember 15, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $8 from $16 at JMP SecuritiesNovember 15, 2024 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Stifel NicolausNovember 15, 2024 | markets.businessinsider.comOptimizeRx's (OPRX) "Buy" Rating Reiterated at Roth MkmRoth Mkm reiterated a "buy" rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday.November 14, 2024 | marketbeat.comStifel Nicolaus Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $8.00Stifel Nicolaus decreased their target price on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday.November 14, 2024 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Given New $5.00 Price Target at BarclaysBarclays dropped their price objective on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday.November 14, 2024 | marketbeat.comJMP Securities Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $8.00JMP Securities lowered their price objective on OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating for the company in a research report on Thursday.November 14, 2024 | marketbeat.comOptimizeRx Reports Strong Revenue Growth in Q3 2024November 14, 2024 | markets.businessinsider.comOptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model ShiftNovember 14, 2024 | markets.businessinsider.comOptimizeRx Corporation (OPRX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comOptimizeRx Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comPreview: OptimizeRx's EarningsNovember 13, 2024 | benzinga.comOptimizeRx (OPRX) Scheduled to Post Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643153)November 6, 2024 | marketbeat.comOptimizeRx (OPRX) Set to Announce Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643153)November 6, 2024 | marketbeat.comRice Hall James & Associates LLC Acquires 119,306 Shares of OptimizeRx Co. (NASDAQ:OPRX)Rice Hall James & Associates LLC raised its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 615,441 shares of the company's stock after acquiring an additional 119,306November 1, 2024 | marketbeat.comOptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ETOctober 31, 2024 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC raised its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 101.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 142,146 shares of the company's stock after buying an additional 71,700 shares during the perioOctober 5, 2024 | marketbeat.comFirst Light Asset Management LLC Purchases 89,377 Shares of OptimizeRx Co. (NASDAQ:OPRX)First Light Asset Management LLC increased its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,826,961 shares of the company's stock after acSeptember 24, 2024 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Shares Sold by Blair William & Co. ILBlair William & Co. IL reduced its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 17.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 643,757 shares of the company's stock after selling 138,816 shares during the quSeptember 21, 2024 | marketbeat.comDivisadero Street Capital Management LP Lowers Stake in OptimizeRx Co. (NASDAQ:OPRX)Divisadero Street Capital Management LP lessened its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 16.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,315,913 shares of the company's stock after selling 256,9September 20, 2024 | marketbeat.comOptimizeRx: A Strong Buy on Client Commitments and Growth PotentialSeptember 11, 2024 | markets.businessinsider.comRice Hall James & Associates LLC Has $4.96 Million Holdings in OptimizeRx Co. (NASDAQ:OPRX)Rice Hall James & Associates LLC increased its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 23.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 496,135 shares of the company's stock after purchasSeptember 11, 2024 | marketbeat.comOptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total ValueSeptember 10, 2024 | globenewswire.comOptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare AudiencesSeptember 9, 2024 | globenewswire.comOptimizeRx (NASDAQ:OPRX) PT Lowered to $14.00 at Royal Bank of CanadaRoyal Bank of Canada decreased their price target on shares of OptimizeRx from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday.August 16, 2024 | marketbeat.comOptimizeRx Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.comOptimizeRx (NASDAQ:OPRX) PT Lowered to $11.00Barclays reduced their target price on shares of OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating for the company in a report on Monday.August 12, 2024 | marketbeat.comEarnings Release: Here's Why Analysts Cut Their OptimizeRx Corporation (NASDAQ:OPRX) Price Target To US$15.79August 11, 2024 | finance.yahoo.comOptimizeRx Corporation (OPRX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comOptimizeRx Maintains Buy Rating: Robust Sales Pipeline and Improved Operational Efficiency Signal Strong Future GrowthAugust 9, 2024 | markets.businessinsider.comOptimizeRx Corporation (NASDAQ:OPRX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comOPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024August 8, 2024 | investorplace.com Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now OPRX Media Mentions By Week OPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPRX News Sentiment▼0.330.57▲Average Computer and Technology News Sentiment OPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPRX Articles This Week▼172▲OPRX Articles Average Week Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IBEX News Absci News Spree Acquisition Corp. 1 News Accolade News Resources Connection News Rimini Street News HireQuest News Mastech Digital News Nutex Health News Tucows News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPRX) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
